Conditions: Parkinson's Disease
Keywords: Parkinson's Disease UPDRS Clinical Global Evaluation Illness Severity score Clinical Global Evaluation Improvement B-SIT SCOPA - Sleep Daytime Sleepiness PDQ -39 SCOPA - Cognition Levodopa rasagiline Dopamine Agonist Therapy monoamine oxidase type B inhibitor
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 328
Healthy volunteers: no

Brief summary:
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.

Detailed description:

Arms:
arm 1: Participants took a 1 mg rasagiline tablet orally each day for 18 weeks. arm 2: Participants took a matching placebo tablet once daily for 18 weeks.

Interventions: intervention 1: Rasagiline intervention 2: Placebo
Intervention descriptions: intervention 1: 1mg tablet daily for 18 weeks intervention 2: one tablet daily for 18 weeks

Protocol document: